Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Skin Neoplasms × Tablets × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 9 Multiple Myeloma 3 Melanoma 3 Venous Thromboembolism 1 Triple Negative Breast Neoplasms 1 Thrombocythemia, Essential 1 Stem Cell Transplant Complications 1 Skin Toxicity 1 Skin Neoplasms 1 Resectable Pancreatic Ductal Adenocarcinoma 1 Renal Insufficiency 1 Recurrence 1 Rectal Neoplasms 1 Prostatic Neoplasms 1 Primary Myelofibrosis 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Polycythemia Vera 1 Polycystic Ovary Syndrome 1 Obesity 1 Neoplasms 1 Myeloproliferative Disorders 1 Meningioma 1 Lymphoma, Mantle-Cell 1 Lung Neoplasms 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Leukemia, B-Cell 1 Leukemia 1 Inflammation 1 Head and Neck Neoplasms 1

Interventions

aldesleukin 15 Cyclophosphamide 13 fludarabine phosphate 10 fludarabine 10 Interleukin-2 10 Nivolumab 7 pembrolizumab 5 Ipilimumab 5 cemiplimab 4 Fluorouracil 4 Aminolevulinic Acid 4 sonidegib 3 Temozolomide 3 Surgical Procedures, Operative 3 Radiotherapy 3 zanolimumab 2 trametinib 2 montanide ISA 51 2 dabrafenib 2 Whole-Body Irradiation 2 Semaxinib 2 Radiation 2 Petrolatum 2 Peptides 2 Gefitinib 2 Cetuximab 2 Capecitabine 2 Axitinib 2 veliparib 1 varlilumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00083239 2007-06-08

Study of Talabostat in Advanced Melanoma

Point Therapeutics

Phase 2 Completed

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡